The combined prevalence of sleep disorders was 43.4% among patients with atopic dermatitis, with variation seen in subgroup analyses.

Kymera Therapeutics announced new clinical trials for KT-621, targeting atopic dermatitis ... as Eczema Area and Severity Index (EASI) and pruritus numerical rating scale (NRS).

Study: Facets of shame and their impact on quality of life in patients with atopic dermatitis and psoriasis ... patients were negligible, disease severity was found to be strongly correlated ...

Kymera reports a narrower-than-expected loss for the first quarter of 2025. The company expects the current cash balance to provide a runway into the first half of 2028.

At week 24, the groups assigned to the IL-4 drug had significantly greater mean reductions in Itch Severity Score over ... occur with CSU -- such as atopic dermatitis and asthma -- providing ...

In April, Kymera initiated dosing in the KT-621 BroADen phase Ib study in moderate to severe atopic dermatitis ... Area and Severity Score and the pruritus numerical rating scale.

With this FDA decision, Dupixent is now approved for seven chronic, debilitating atopic conditions driven in part by ... in itch at 24 weeks (measured by the weekly itch severity score, 0-21 scale).

The Dupixent group also saw a 15.9-point reduction in itch and hive severity (on a 42-point ... The others are atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, eosinophilic ...

SAD/MAD Phase 1 healthy volunteer trial with data to be reported in June 2025 First patient dosed in KT-621 (STAT6) BroADen Phase 1b trial in moderate to severe atopic dermatitis ...

Data from icotrokinra ICONIC-TOTAL show 66% of patients with scalp psoriasis and 77% with genital psoriasis achieved site-specific clear or almost clear skin at Week 16Icotrokinra continues to ...

Though not yet approved, investors are already eyeing the drug as a potential blockbuster. Its commercial rights holder in ...